NCT03895112View on ClinicalTrials.gov

MPN-RC 118 AVID200 in Myelofibrosis

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

February 15, 2019

Primary Completion Date

May 16, 2022

Study Completion Date

May 16, 2022

Conditions
Primary MyelofibrosisPost-essential Thrombocythemia MyelofibrosisPost-polycythemia Vera MyelofibrosisPost ET MFPost PV MF
Interventions
DRUG

AVID200

dose cohorts of 21-day cycles

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Formation Biologics
All Listed Sponsors
collaborator

Formation Biologics

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Myeloproliferative Neoplasm Research Consortium (MPN-RC)

UNKNOWN

lead

John Mascarenhas

OTHER

NCT03895112 - MPN-RC 118 AVID200 in Myelofibrosis | Biotech Hunter | Biotech Hunter